1. Home
  2. CTNM vs SIGIP Comparison

CTNM vs SIGIP Comparison

Compare CTNM & SIGIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • SIGIP
  • Stock Information
  • Founded
  • CTNM 2009
  • SIGIP N/A
  • Country
  • CTNM United States
  • SIGIP United States
  • Employees
  • CTNM N/A
  • SIGIP 2800
  • Industry
  • CTNM
  • SIGIP Property-Casualty Insurers
  • Sector
  • CTNM
  • SIGIP Finance
  • Exchange
  • CTNM Nasdaq
  • SIGIP Nasdaq
  • Market Cap
  • CTNM 114.1M
  • SIGIP N/A
  • IPO Year
  • CTNM 2024
  • SIGIP N/A
  • Fundamental
  • Price
  • CTNM $3.87
  • SIGIP $17.23
  • Analyst Decision
  • CTNM Strong Buy
  • SIGIP
  • Analyst Count
  • CTNM 4
  • SIGIP 0
  • Target Price
  • CTNM $23.75
  • SIGIP N/A
  • AVG Volume (30 Days)
  • CTNM 86.8K
  • SIGIP N/A
  • Earning Date
  • CTNM 05-16-2025
  • SIGIP N/A
  • Dividend Yield
  • CTNM N/A
  • SIGIP N/A
  • EPS Growth
  • CTNM N/A
  • SIGIP N/A
  • EPS
  • CTNM N/A
  • SIGIP N/A
  • Revenue
  • CTNM N/A
  • SIGIP N/A
  • Revenue This Year
  • CTNM N/A
  • SIGIP N/A
  • Revenue Next Year
  • CTNM N/A
  • SIGIP N/A
  • P/E Ratio
  • CTNM N/A
  • SIGIP N/A
  • Revenue Growth
  • CTNM N/A
  • SIGIP N/A
  • 52 Week Low
  • CTNM $3.69
  • SIGIP N/A
  • 52 Week High
  • CTNM $22.00
  • SIGIP N/A
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • SIGIP 43.17
  • Support Level
  • CTNM N/A
  • SIGIP $17.06
  • Resistance Level
  • CTNM N/A
  • SIGIP $17.40
  • Average True Range (ATR)
  • CTNM 0.00
  • SIGIP 0.17
  • MACD
  • CTNM 0.00
  • SIGIP 0.03
  • Stochastic Oscillator
  • CTNM 0.00
  • SIGIP 30.14

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About SIGIP Selective Insurance Group Inc. Depositary Shares each representing a 1/1000th interest in a share of 4.60% Non-Cumulative Preferred Stock Series B

Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, Investments. Majority of revenue is gained from Standard Personal Lines. Currently company has it's revenues from States of USA and Columbia.

Share on Social Networks: